Gary Dahl | Academic Influence

Q: What Schools Are Affiliated With Gary Dahl

Gary Dahl is affiliated with the following schools: University of Alabama, University of California, Berkeley, Stanford University

Why Is Gary Dahl Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Gary Ross Dahl was an American businessman and advertising director. He founded and created the collectable toy Pet Rock—smooth stones from the city of Rosarito, Baja California, Mexico, in the mid-1970s—which was successful enough to make him a millionaire.

(See a Problem?)

Gary Dahl 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. (2010) (475)
Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. (1989) (439)
New chromosomal translocations correlate with specific immunophenotypes of childhood acute lymphoblastic leukemia (1984) (350)
A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. (2006) (281)
Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. (1985) (265)
Critical windows of exposure to household pesticides and risk of childhood leukemia. (2002) (230)
Profile of daily life in children with brain tumors: an assessment of health-related quality of life. (2005) (208)
The incidence and clinical significance of nucleophosmin mutations in childhood AML. (2007) (206)
The Genomic Landscape of Juvenile Myelomonocytic Leukemia (2015) (204)
A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. (1999) (188)
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. (2012) (173)
Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. (2007) (170)
Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000 (2005) (170)
Heavy chain immunoglobulin gene rearrangement in acute nonlymphocytic leukemia. (1984) (170)
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. (2010) (165)
Childhood acute lymphocytic leukemia. Study VIII (1978) (163)
Chromosomal translocations play a unique role in influencing prognosis in childhood acute lymphoblastic leukemia. (1986) (158)
Aneuploidy and percentage of S-phase cells determined by flow cytometry correlate with cell phenotype in childhood acute leukemia. (1982) (157)
Attitudes and practices of pediatric oncology providers regarding fertility issues (2007) (144)
An analysis of leukemic cell chromosomal features in infants. (1987) (142)
A prospective study of Hickman/Broviac catheters and implantable ports in pediatric oncology patients. (1989) (140)
Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. (2000) (130)
Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. (1998) (130)
Concerns about infertility risks among pediatric oncology patients and their parents (2008) (123)
Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. (1990) (121)
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. (2004) (121)
Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. (2012) (121)
Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. (2010) (121)
Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. (2006) (111)
Transient leukemoid reaction and trisomy 21 mosaicism in a phenotypically normal newborn. (1980) (111)
Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. (2004) (110)
The t(1;22) (p13;q13) Is Nonrandom and Restricted to Infants With Acute Megakaryoblastic Leukemia: A Pediatric Oncology Group Study (1991) (103)
Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude total therapy study X. (1992) (86)
Acute leukaemia with mixed lymphoid and myeloid phenotype (1984) (85)
Glucocorticoid receptors in childhood acute lymphocytic leukemia. (1982) (82)
Prenatal origin of childhood acute myeloid leukemias harboring chromosomal rearrangements t(15;17) and inv(16). (2003) (81)
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. (2006) (76)
Outcomes of transplantation in children with primary hepatic malignancy (2007) (73)
Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission. (1990) (73)
Serum lactic dehydrogenase level has prognostic value in childhood acute lymphoblastic leukemia. (1985) (70)
Combined VM‐26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia (1980) (68)
Cytogenetic features of acute nonlymphoblastic leukemia in 73 children and adolescents. (1983) (68)
VM‐26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia (1980) (67)
ACUTE LEUKAEMIA WITH MIXED LYMPHOID AND MYELOID PHENOTYPE (1984) (65)
Central Nervous System Leukemia in Children with Acute Nonlymphoblastic Leukemia (1985) (64)
Effect of body mass index on the outcome of children with acute myeloid leukemia (2012) (63)
Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide. (1988) (63)
Cytogenetic features and serum lactic dehydrogenase level predict a poor treatment outcome for children with pre-B-cell leukemia. (1986) (62)
The relationship of blast cell glucocorticoid receptor levels to response to single-agent steroid trial and remission response in children with acute lymphoblastic leukemia. (1984) (62)
ELECTIVE TESTICULAR BIOPSY DURING CHEMOTHERAPY FOR CHILDHOOD LEUKAEMIA IS OF NO CLINICAL VALUE (1985) (61)
Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. (2008) (60)
Neoplastic Disorders After Pediatric Heart Transplantation (1993) (60)
Clinical relevance of lymphoblast biological features in children with acute lymphoblastic leukemia. (1985) (60)
Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia (1978) (58)
Weekly Dosing of Carboplatin Increases Risk of Allergy in Children (2001) (57)
Acute nonlymphoblastic leukemia in infants: clinical presentation and outcome. (1988) (57)
Cytokinetically based induction chemotherapy and splenectomy for childhood acute nonlymphocytic leukemia. (1982) (55)
The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. (1991) (54)
Associations between genome-wide Native American ancestry, known risk alleles and B-cell ALL risk in Hispanic children (2013) (53)
A novel treatment of childhood lymphoblastic non-Hodgkin's lymphoma: early and intermittent use of teniposide plus cytarabine. (1985) (52)
Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. (2000) (50)
Epidural spinal cord compression as the initial finding in childhood acute leukemia and non-Hodgkin lymphoma. (1985) (50)
Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate‐use trial (2014) (50)
Unfavorable presenting clinical and laboratory features are associated with CALLA-negative non-T, non-B lymphoblastic leukemia in children. (1986) (50)
Childhood monosomy 7 syndrome: clinical and in vitro studies. (1987) (47)
Novel childhood ALL susceptibility locus BMI1-PIP4K2A is specifically associated with the hyperdiploid subtype. (2013) (47)
Acute vincristine neurotoxicity in the presence of hereditary motor and sensory neuropathy type I. (1989) (46)
In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia. (2017) (46)
Recurrent childhood lymphocytic leukemia. Clinical and cytokinetic studies of cytosine arabinoside and methotrexate for maintenance of second hematologic remission (1978) (46)
Residential Levels of Polybrominated Diphenyl Ethers and Risk of Childhood Acute Lymphoblastic Leukemia in California (2014) (46)
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia (2008) (45)
Childhood Leukemia: A Preventable Disease (2016) (44)
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia (2013) (44)
Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemia. (1984) (44)
Serum levels of CD8 antigen in childhood lymphoid malignancies: a possible indicator of increased suppressor cell activity in poor-risk patients. (1988) (44)
Altered resting state functional connectivity in young survivors of acute lymphoblastic leukemia (2014) (42)
Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children’s Oncology Group Study POG 9421 (2013) (41)
Concurrent Treatment of Steroid-Related Mood and Psychotic Symptoms With Risperidone (2010) (41)
Variation by race in presenting clinical and biologic features of childhood acute lymphoblastic leukaemia: implications for treatment outcome. (1985) (41)
Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. (2009) (38)
Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia. (1985) (37)
WT1 expression at diagnosis does not predict survival in pediatric aml: A report from the Children's Oncology Group (2009) (35)
Proteomic analysis of childhood leukemia (2005) (33)
Variation in xenobiotic transport and metabolism genes, household chemical exposures, and risk of childhood acute lymphoblastic leukemia (2012) (33)
Phase I study of valspodar (PSC‐833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children's Oncology Group (2010) (33)
Treatment outcome in older patients with childhood acute myeloid leukemia (2012) (32)
Surveillance neuroimaging to detect relapse in childhood brain tumors: a Pediatric Oncology Group study. (2001) (31)
Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy (2015) (31)
Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia. (2008) (31)
Phase I clinical and pharmacokinetic study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in children with cancer. (1980) (30)
Childhood acute promyelocytic leukemia: a rare variant of nonlymphoid leukemia with distinctive clinical and biologic features. (1989) (30)
Small Molecule Inhibition of cAMP Response Element Binding Protein in Human Acute Myeloid Leukemia Cells (2016) (30)
Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia. (2017) (30)
Clinical significance of low levels of myeloperoxidase positivity in childhood acute nonlymphoblastic leukemia (1987) (30)
Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine. (1981) (29)
Teniposide (VM26) disposition in children with leukemia. (1984) (29)
Clinical utility of initial terminal deoxynucleotidyl transferase determinations in childhood acute leukemias. (1981) (28)
Genomic ancestry and somatic alterations correlate with age at diagnosis in Hispanic children with B‐cell acute lymphoblastic leukemia (2014) (27)
A syndrome of irreversible leukoencephalopathy following pediatric allogeneic bone marrow transplantation (2007) (27)
Second central nervous system prophylaxis in children with acute lymphoblastic leukemia who relapse after elective cessation of therapy. (1983) (27)
Management of children with metastatic spinal myxopapillary ependymoma using craniospinal irradiation. (2000) (27)
HLA-DP genetic variation, proxies for early life immune modulation and childhood acute lymphoblastic leukemia risk. (2012) (27)
Second cessation of therapy in childhood lymphocytic leukemia. (1979) (26)
Central nervous system leukemia in children with acute nonlymphoblastic leukemia. (1985) (24)
Children’s Cancer and Environmental Exposures: Professional Attitudes and Practices (2015) (23)
Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways (2017) (22)
Modified Cyclophosphamide, Hydroxydaunorubicin, Vincristine, and Prednisone Therapy for Posttransplantation Lymphoproliferative Disease in Pediatric Patients Undergoing Solid Organ Transplantation (2001) (20)
Early results of intensified remission induction chemotherapy for childhood acute lymphocytic leukemia. (1986) (20)
Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine. (1986) (19)
Response of recurrent acute lymphoblastic leukemia to glucocorticoids: serial studies of receptor content, in vivo cytokinetic changes and clinical responses. (1983) (18)
Relationship of megakaryocyte size at diagnosis to chemotherapeutic response in children with acute nonlymphocytic leukemia. (1983) (17)
Glucocorticoid receptors in childhood acute non-lymphocytic leukemia. (1983) (16)
Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood. (1982) (16)
Minimal Residual Disease–Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial. (2009) (15)
Cytogenetic Variation of B-Lymphoblastic Leukemia With Intrachromosomal Amplification of Chromosome 21 (iAMP21): A Multi-Institutional Series Review. (2015) (15)
Development and validation of a single‐cell network profiling assay‐based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group (2013) (15)
Pediatric acute myeloid leukemia as classified using 2008 WHO criteria: a single-center experience. (2013) (14)
Cyclophosphamide/etoposide: effective reinduction therapy for children with acute nonlymphocytic leukemia in relapse. (1985) (13)
Phase I-II study of continuous-infusion high-dose human lymphoblastoid interferon and the in vitro sensitivity of leukemic progenitors in nonlymphocytic leukemia. (1986) (12)
VM-26 with prednisone and vincristine for treatment of refractory acute lymphocytic leukemia. (1982) (12)
Methotrexate plus L‐asparaginase. An active combination for children with acute nonlymphocytic leukemia (1990) (11)
VM26 therapy in children with drug-refractory lymphocytic leukemia (2004) (10)
Auer rods in mature granulocytes: a unique morphologic feature of acute myelogenous leukemia with maturation. (1984) (10)
Ultrastructure and cytokinetics of leukemic myeloblasts containing giant granules. (1979) (10)
Limiting toxicities during intensified remission induction chemotherapy for childhood acute lymphocytic leukemia. (1987) (9)
Identification of a novel p53 in‐frame deletion in a Li–Fraumeni‐like family (2008) (9)
Dust metal loadings and the risk of childhood acute lymphoblastic leukemia (2015) (9)
Testicular relapse in children with acute nonlymphoblastic leukemia (1990) (9)
BCL-2 expression does not correlate with patient outcome in pediatric acute myelogenous leukemia (1998) (9)
Improved Remission Induction Rate of Childhood AML: Preliminary Results of the AML02 Trial. (2005) (9)
Hemothorax and hemomediastinum in patients with hemophilia. (1985) (9)
Phase II study of 2‐chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a Paediatric Oncology Group study (2012) (9)
Recurrent mercaptopurine-induced acute pancreatitis: a rare complication of chemotherapy for acute lymphoblastic leukemia in children. (2002) (8)
Determination of the significance of in vitro blast cell [3H]thymidine labelling indices obtained initially and serially during induction therapy of acute non-lymphocytic leukemia. (1982) (8)
Recent results from Total Therapy Study X for standard and high risk acute lymphoblastic leukemia in children: recognition of new clinical and biologic risk features. (1985) (8)
Concurrent cyclophosphamide and craniospinal radiotherapy for pediatric high-risk embryonal brain tumors (2012) (7)
Forodesine in Patients with Refractory/Relapsed T-ALL Can Induce Prolonged Stable Remission with Minimal Toxicity before and after Allogeneic Hematopoietic Stem Cell Transplantation. (2006) (7)
Pseudomonas aeruginosa infection with marrow suppression simulating acute promyelocytic leukemia. (1983) (7)
Tissue Microarrays from Bone Marrow Aspirates for High-Throughput Assessment of Immunohistologic Markers in Pediatric Acute Leukemia (2008) (7)
Reinduction of relapsed acute promyelocytic leukemia with ATRA and low dose antimetabolite‐based chemotherapy (2007) (7)
Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia (2004) (6)
Comparison of the Transcriptomic Signatures in Pediatric and Adult CML (2020) (5)
Cytokine Levels at Birth in Children Who Developed Acute Lymphoblastic Leukemia (2021) (5)
Excessive Cardiotoxicity Despite Excellent Leukemia-Free Survival for Pediatric Patients with Down Syndrome (DS) and Acute Myeloid Leukemia (AML): Results from POG (Pediatric Oncology Group) Protocol 9421. (2006) (5)
Langerhans cell histiocytosis in a 5-month-old presenting with biparietal masses. (2010) (4)
BCL-2 expression does not not correlate with patient outcome in pediatric acute myelogenous leukemia. (1998) (4)
Biology and therapy of childhood acute nonlymphocytic leukemia. (1988) (4)
Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421 (2010) (4)
Acute Megakaryoblastic Leukemia (AMKL) in Children without Down Syndrome. (2009) (4)
Pilot undergraduate course teaches students about chronic illness in children: An educational intervention study (2014) (3)
Peripheral blood lymphocyte populations in influenza patients. (1977) (3)
Correction: Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia (2016) (3)
["Total therapy" for localized and regional malignant non-Hodgkin's lymphoma of children. A second look (author's transl)]. (1979) (3)
Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine (2004) (3)
Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells (2018) (3)
Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results, (2011) (2)
Therapeutic complications in a patient with high‐risk acute lymphoblastic leukemia and undiagnosed hereditary hemochromatosis (2012) (2)
Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421. (2005) (2)
Prolonged second marrow remission in children with lymphocytic leukemia (ALL) treated with VM-26 and cytosine arabinoside (ara-C) (1981) (2)
Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421. (2006) (2)
What causes leukemia? (2015) (2)
Female Gender and Hispanic Ethnicity are Associated with Increased Risk of Subacute Methotrexate Encephalopathy (2015) (2)
Mitoxantrone, Etoposide and Cyclosporine A Therapy for Relapsed and Refractory Acute Myelogenous Leukemia, A Pediatric Oncology Group Phase II Trial (1996) (2)
L-Asparaginase (L-ASP) Related Toxicities with Asparaginase Erwinia Chrysanthemi in a Large Compassionate Use Protocol. (2012) (1)
Correlation of a family history of cancer with risk of relapse and death in pediatric cancer patients. (2009) (1)
Teniposide ( VM 26 ) Disposition in Children with Leukemia 1 (2006) (1)
Therapy‐related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature (2021) (1)
A germ-line deletion of APOBEC3B does not contribute to subtype-specific childhood acute lymphoblastic leukemia etiology (2018) (1)
LEADING ARTICLE Proteomic analysis of childhood leukemia (2005) (1)
CpG Island Methylator Phenotype and Childhood Leukemia (2006) (1)
Molecular Inversion Probes (MIPs) Identify Novel Areas of Allelic Imbalance in Childhood Leukemia. (2007) (1)
FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421. (2004) (1)
594 HIGH RISK ACUTE LYMPHOCYTIC LEUKEMIA (ALL): PROBLEM OF EARLY RELAPSE (1978) (1)
Chromatin Remodeling Therapy and Capizzi Methotrexate in Treatment-Related MDS/AML (2018) (1)
POSSIBLE PROGNOSTIC INDICATOR FOR HIGH RISK CHILDHOOD ACUTE LYMPHOCYTIC LEUKAEMIA PATIENTS (1983) (1)
Adapting molecular inversion probe (MIP) technology for allele quantification in childhood leukemia (2007) (1)
Array CGH Discovers Novel Genomic Signatures in De Novo Acute Myeloid Leukemia (AML): Results of Children’s Oncology Group (COG) Study POG #9421. (2005) (0)
Multidrug Resistance Reversal Utilizing Mitoxantrone, Etoposide and Continuous Infusion Cyclosporine in Pediatric ANLL (1994) (0)
Nonlymphoid Leukemias in Children. C. Pochedly, ed. New York: Praeger Publishers, 1985. 231 pp (1987) (0)
TBI and Allogeneic BMT Do Not Appear To Hinder Growth in Pediatirc Patients with AML Treated on POG 9421 (Now Children’s Oncology Group). (2006) (0)
Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group). (2004) (0)
The incidence and clinical significance of nucleophosmin mutations in (2013) (0)
Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421. (2004) (0)
Novel Allele Quantification Method To Classify Childhood Leukemia. (2006) (0)
Surveillance N euroimaging t o D etect R elapse i n C hildhood Brain T umors: A P ediatric O ncology G roup S tudy (2001) (0)
2008 WHO Classification of Pediatric AML. (2010) (0)
Osteonectin/SPARC Is Epigenetically Silenced in AML with MLL Gene Rearrangements and Selectively Inhibits the Growth of MLL Rearranged Cell Lines. (2004) (0)
Next-Generation Sequencing of Immunoglobulin Heavy Chain Variable Region in Diagnostic Samples of Pediatric Acute Lymphoblastic Leukemia Identifies Hundreds of Clonal Subpopulations with Multiple Immunophenotypes (2011) (0)
Use Of Rearranged Immune Receptor Sequencing To Measure Minimal Residual Disease (MRD) In Bone Marrow, Cerebrospinal Fluid and Testes In Relapsed Childhood Acute Lymphoblastic Leukemia (2013) (0)
patients possible indicator of increased suppressor cell activity in poor-risk Serum levels of CD8 antigen in childhood lymphoid malignancies: a (2011) (0)
Gene Expression Analysis of CML Patients across the Age Spectrum (2021) (0)
469 Chemotherapy improves survival in pediatric post transplant lymphoproliferative disease unresponsive to immunosuppression reduction (1999) (0)
Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase (2003) (0)
Glucocorticoid Receptors in Childhood Acute Lymphocytic Leukemia 1 (2006) (0)
Phase I Clinical and Pharmacokinetic Study of 4'-(9-Acridinylamino)-methanesulfon-m-anisidide in Children with Cancer1 (2006) (0)
Single Institution Experience With Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and AYA Patients With Acute Leukemia (2013) (0)
747Implementation of weight-based blood culture collection in pediatric hematology/oncology patients (2014) (0)
We thank physicians and hospitals in California who contrib- uted diagnostic material to this study. We thank the California Department of Health Services for access to Guthrie cards. (2003) (0)
cooperative trials for de novo AML patients with core binding factor AML enrolled on serial pediatric mutations in pediatric KIT Prevalence and prognostic significance of (2011) (0)
LYMPHOID NEOPLASIA In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia (2017) (0)
In cyclosporine‐induced neurotoxicity, is tacrolimus an appropriate substitute or is it out of the frying pan and into the fire?—Response (2008) (0)
Treatment of High-Risk Pre-B Acute Lymphoblastic Leukemia in a Fanconi Anemia Patient With Reduced-Intensity Chemotherapy (2013) (0)
Comparison of the Transcriptomic Signatures in Pediatric and Adult CML (2021) (0)
Clinical relevance of P-gp expression in pediatric myeloid leukemia [11] (2006) (0)
Variation in xenobiotic transport and metabolism genes, household chemical exposures, and risk of childhood acute lymphoblastic leukemia (2012) (0)
1144 POSTER Using Single-cell Network Profiling (SCNP) Signatures to Predict Response to Induction Therapy and Relapse Risk in Pediatric Patients With Acute Myeloid Leukemia (AML) (2011) (0)
Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort (2012) (0)
Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy (2013) (0)
Safety of asparaginase Erwinia chrysanthemi in a compassionate-use trial: Subanalysis of the adolescent/young adult (AYA) and adult patient (Pt) population. (2013) (0)
normal newborn Transient leukemoid reaction and trisomy 21 mosaicism in a phenotypically (2011) (0)
CURRENT KNOWLEDGE ON “ ACTIONABLE ” RISK FACTORS OF CHILDHOOD LEUKEMIA (2016) (0)
L-asparaginase (L-ASP)-related toxicities with Erwinia L-ASP in a large compassionate-use protocol. (2011) (0)

This paper list is powered by the following services:

Other Resources About Gary Dahl

en.wikipedia.org

What Schools Are Affiliated With Gary Dahl ?

Gary Dahl is affiliated with the following schools: